menu
    • menu

    Company profile for Atsena Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the...
    Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.Founded by pioneers in ocular gene therapy, Atsena ,and is headquartered in North Carolina

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Atsena TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    8 Davis Drive, Suite 300, Durham, NC 27709
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://atsenatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atsenatx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atsena Completes Adult Dosing In Atsn-201 Trial For X-Linked
    Atsena Completes Adult Dosing In Atsn-201 Trial For X-Linked

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3154582/0/en/Atsena-Therapeutics-Announces-Dosing-Complete-for-Adults-in-Part-B-of-the-Phase-I-II-III-LIGHTHOUSE-Trial-Evaluating-ATSN-201-to-Treat-X-linked-Retinoschisis.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    Atsena Therapeutics, FDA Align on ATSN-201 Approval Path for XLRS
    Atsena Therapeutics, FDA Align on ATSN-201 Approval Path for XLRS

    09 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/09/3112470/0/en/Atsena-Therapeutics-Announces-Alignment-with-FDA-on-Regulatory-Pathway-to-Approval-for-ATSN-201-in-X-Linked-Retinoschisis-XLRS.html

    GLOBENEWSWIRE
    09 Jul 2025
    Share Share
    Atsena gene therapy hits safety goals, closes retinal splits
    Atsena gene therapy hits safety goals, closes retinal splits

    20 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/atsena-eye-disease-gene-therapy-hits-safety-goals-closes-retinal-splits-7-9-patients

    FIERCE BIOTECH
    20 May 2025
    Share Share
    Atsena Therapeutics to Present at May Scientific Conferences
    Atsena Therapeutics to Present at May Scientific Conferences

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070063/0/en/Atsena-Therapeutics-to-Present-at-May-Scientific-Conferences.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Atsena Gets RMAT Tag for Gene Therapy in Retinoschisis
    Atsena Gets RMAT Tag for Gene Therapy in Retinoschisis

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061608/0/en/Atsena-Therapeutics-Granted-U-S-FDA-Regenerative-Medicine-Advanced-Therapy-Designation-for-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Atsena Therapeutics Raises $150M in Series C Financing
    Atsena Therapeutics Raises $150M in Series C Financing

    02 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/02/3054152/0/en/Atsena-Therapeutics-Announces-Oversubscribed-150-Million-Series-C-Financing-to-Further-Advance-Ocular-Gene-Therapy-Programs.html

    GLOBENEWSWIRE
    02 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search